Fig. 7.

GSK2193874 inhibits NLRP3 inflammasome expression and pro-inflammatory cytokine production in rat hippocampus after soman exposure. Soman group: rats were treated with HI-6 (125 mg/kg i.p.) before soman injection (160 μg/kg, s.c.); GSK2193874 (GSK) group: rats were additionally treated with the TRPV4 antagonist GSK2193874 (1 mg/kg, i.v.) immediately after HI-6 injection and before soman injection; Control group: rats received HI-6 and solvent instead of the antagonist and soman. (A–F) Western blots (A) and analysis of NLRP3 (B), ASC (C), caspase-1 (D), IL-1β (E), IL-18 (F), and β-actin protein levels (mean ± SD, n = 3; *P <0.05, ***P <0.001 vs control group, ^#P <0.05, ^###P <0.001 vs soman group, one-way ANOVA and Dunnett’s multiple comparison test).